This article is more than 5 years old. Information may no longer be current.

Alcon AcrySof IOLs show positive refractive outcomes

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alcon’s AcrySof IQ monofocal IOL and AcrySof IQ PanOptix trifocal IOL both had positive results in studies presented at the European Society of Cataract and Refractive Surgeons meeting, according to a press release.

An analysis of 151 patients who received the AcrySof IQ PanOptix trifocal IOL found a significant improvement in visual acuity at 12 months after surgery, with both corrected and uncorrected vision reaching 20/25 or better across near, intermediate and distance, the release said.

“These robust data show that the PanOptix trifocal lens enabled patients to achieve excellent results in visual acuity, especially at an intermediate distance of 60 cm,” lead study author Thomas Kohnen, MD, PhD, FEBO, chair of the department of ophthalmology at Goethe University, Frankfurt, said in the release. “PanOptix proves to be a valuable option for those looking for less dependence on spectacles in their everyday life.”

In a separate retrospective study, patients who received the AcrySof monofocal IOL were shown over 5 years to be less likely to develop posterior capsule opacification after cataract surgery compared with those implanted with other monofocal hydrophilic or hydrophobic IOLs, according to the release.